Nadia P. Ewing, M.D.

  • Director, Hemophilia and Sickle Cell Programs
  • Clinical Professor of Pediatrics
  • Pediatric Hematologist

Nadia P. Ewing, M.D.

Clinical Specialties
  • Pediatric Hematology-Oncology
Areas of Expertise
  • Hemophilia and Sickle Cell Disease
  • Hematology/Oncology
Research Focus
  • Gene Therapy in Hemophilia
  • Induction of Immune Tolerance in Patients with Hemophilia and Inhibitors
  • Management of Inhibitors in Hemophilia
  • Prophylaxis in Hemophiliacs with Inhibitors
  • Genetics of Inhibitor Formation in Hemophilia
Other Languages Spoken
  • Spanish
  • Italian
Nadia Ewing, M.D., is a clinical professor of Pediatrics and director of the Pediatric Hemophilia Treatment Center at City of Hope, where she also serves as director of the Sickle Cell Program and Pediatric Hematology Consultations. Dr. Ewing earned her medical degree at the University of Southern California (USC) in Los Angeles. She completed an internship and residency in pediatrics, followed by a fellowship in Pediatric Hematology/Oncology at the Los Angeles County/USC Medical Center.
Dr. Ewing is a member of the International Society on Thrombosis and Haemostasis, the Hemostasis and Thrombosis Research Society, the American Society of Hematology, The American Society of Pediatric Hematology/Oncology and the World Federation of Hemophilia. Her research interests include gene therapy in hemophilia, management of inhibitors in hemophilia, and genetics of inhibitor formation in hemophilia. She has written articles in The New England Journal of Medicine, the Journal of Pediatric Hematology/Oncology and Haemophilia. Dr. Ewing has presented abstracts for the American Society of Hematology, ISTH, and the Hemostasis and Thrombosis Research Society.
  • 1996-present, Director, Pediatric Hemophilia and Sickle Cell Programs and Pediatric Hematology Consultations, City of Hope, Duarte, California
  • 1989 – 1995, Director, Huntington Hospital Pediatric Hematology/Oncology Center, Pasadena, California
  • 1989 - 1995, Pediatric Hematologist, Huntington Hospital Hemophilia Center, Pasadena, California
  • 1980 – 1988, Director of Pediatric Care, Hemophilia Center, Orthopaedic Hospital, Los Angeles, California
  • 1986 – 1988, Director, Pediatric Sickle Cell Disease Center, Orthopaedic Hospital, Los Angeles, California
  • 1980 - 1988, Co-director of California Children Services Tumor Center, Orthopaedic Hospital, Los Angeles, California


City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA, 91010

Get Directions

Phone :  626-256-4673


  • 1967, University of Southern California, Los Angeles, California, B.A., Zoology
  • 1967 -1971, University of Southern California, Los Angeles, California, M.D., Medicine


  • 1978-80: Pediatric Hematology/Oncology -- Los Angeles County/ University of Southern California Medical Center, Los Angeles, CA


  • 1977-78: Pediatrics -- Los Angeles County/University of Southern California Medical Center, Los Angeles, CA
  • 1987, American Board of Pediatrics, Sub-Board of Pediatric Hematology/Oncology
  • 1981, American Board of Pediatrics

Information listed here is obtained from Pubmed, a public database; City of Hope is not responsible for its accuracy.

Haemophilia. 2015 May;21(3):358-64. doi: 10.1111/hae.12602. Epub 2015 Jan 21.
Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors.
Authors: Ewing N1, Escuriola-Ettingshausen C, Kreuz W.
The benefits shown with factor VIII (FVIII) prophylaxis relating to joint health and quality of life (QoL) provide the rationale for FEIBA prophylaxis in haemophilia A patients with persistent FVIII inhibitors. FEIBA has previously shown efficacy in preventing bleeds in inhibitor patients who failed to respond to, or were ineligible for immune tolerance induction (ITI). The study examined the outcome of paediatric patients undergoing long-term FEIBA prophylaxis. A retrospective chart review included severe haemophilia A patients with persistent inhibitors aged ≤13 years at the start of FEIBA prophylaxis. Baseline characteristics captured dose, frequency of prophylaxis, history of inhibitor development, including baseline titre, historical peak titre and history of ITI. Outcome measurements included annual bleed rate before and during FEIBA prophylaxis, joint status and school days missed. Sixteen cases of FEIBA prophylaxis from two centres are presented. The mean age of subjects at prophylaxis initiation was 7.5 ± 3.6 years and median baseline inhibitor titre was 23 (range 3.1-170) BU. Prior to prophylaxis initiation, median annual joint bleeds among all patients was 4 (0-48), which dropped significantly after the first year of prophylaxis, to a median annual joint bleed rate of 1 (0-7; P = 0.0179). Subsequent years (median = 9) of prophylaxis therapy demonstrated similarly low annual joint bleed rates. There were no life-threatening bleeds, no viral seroconversions or thrombotic events during FEIBA prophylaxis treatment. FEIBA prophylaxis was effective for preventing joint bleeds and subsequent joint damage, delaying arthropathy and improving outcomes in children with haemophilia A and inhibitors to FVIII, who failed or were ineligible for ITI.
© 2015 The Authors. Haemophilia Published by John Wiley & Sons Ltd.
PMID: 25603840 DOI: 10.1111/hae.12602
[Indexed for MEDLINE]
  • International Society of Thrombosis and Hemostasis
  • SSC Working Group: Prophylaxis in Patients with Hemophilia and Inhibitors
  • American Society of Hematology
  • American Society of Pediatric Hematology and Oncology
  • American Academy of Pediatrics
  • World Federation of Hemophilia
  • National Hemophilia Foundation
  • Hemostasis and Thrombosis Research Society
  • World Immune Tolerance Study Group
  • Region IX Coordinating Committee
  • International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Los Angeles County Medical Association
Back To Top